5 резултати
PRIMARY OBJECTIVES:
I. To evaluate the ability of histone deacetylase (HDAC) inhibition using suberoylanilide hydroxamic acid (SAHA) (vorinostat) to induce expression of the estrogen receptor (ER) and progesterone receptor (PR) genes in solid human triple negative invasive breast
In the United States, the incidence of acute myeloid leukemia (AML) is approximately 3.5 cases per 100,000 persons per year. Approximately 13,000 people were diagnosed with AML in 2009 and 9,000 died of the disease, making AML the 6th leading cause of cancer death. Over the past three decades, AML
Key eligibility criteria include:
- Newly diagnosed invasive breast cancer awaiting surgery or neoadjuvant (preoperative) treatment
- No use of hormone contraceptives or replacement therapy within 30 days prior to the diagnostic breast cancer biopsy (unless willing to have an additional biopsy prior
PRiMARY OBJECTIVES:
I. To determine the recommended phase II dose of oral suberoylanilide hydroxamic acid (vorinostat) in combination with weekly paclitaxel and bevacizumab in patients with chest wall recurrent or metastatic breast cancer. (Phase I) II. To determine the efficacy (response rate,
PRIMARY OBJECTIVES:
I. To evaluate the response rate in patients receiving SAHA for stage IV breast cancer.
SECONDARY OBJECTIVES:
I. Time to progression. II. Overall survival. III. Toxicity profile. IV. Assessment of potential biological correlates.
OUTLINE: This is a multicenter study.
Patients